Samumed

Samumed is a leader in tissue-level regenerative medicine research and development. Originating from our platform based on small-molecule Wnt pathway modulation, we have developed therapies that address a range of degenerative diseases, regenerative medicine, and oncology. Founded in 2008 in San Diego, California, Samumed adopted a fresh business philosophy from the start, aiming to build a broad technology platform designed to modulate regenerative pathways to improve patient health. As an independent and management-controlled company, Samumed fully leverages its ability to execute a unique long-term vision. Scientific innovation remains the cornerstone of our company as we discover and develop various drug candidates. Our integrated approach begins in our laboratories, proceeds through clinical studies, and extends to commercialization.